No Detail Found!

Exploring the role of immune checkpoint inhibitors in combination with conventional DMARDS for treating rheumatoid arthritis

Author(s)
Qing Lu Orthopedics and Traumatology Department of Traditional Chinese Medicine, The 3rd People's Hospital of Xiangcheng District in Suzhou, Suzhou, Jiangsu Province, China
Yunyun Lin Department of General Practice Medicine, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
Abstract
Rheumatoid arthritis (RA) is chronic autoimmune disorder leading to joint damage and systemic complications. This study aimed to explore the clinical effectiveness of combining immune checkpoint inhibitors (ICIs) with conventional disease-modifying antirheumatic drugs (DMARDs) in patients diagnosed with RA. A total of 50 patients undergoing cancer treatment with ICIs were enrolled in this observational study. Demographic and clinical data were collected. Patients receiving ICI therapy were concomitantly managed with conventional DMARDs, with treatment initiation and duration recorded. Response to therapy was assessed over a follow-up period of 60 days using clinical improvement scores. The mean age of the patients was 59.5 years, with males comprising 56% and smoking history comprising 62% of patients. Melanoma (36%) and renal carcinoma (30%) were the most common malignancies. Most patients were in stage III cancer, with 16% showing brain metastases. Grade 3 arthritis was present in 42% of the cohort. Kaplan-Meier survival estimates showed time to arthritis control within 60 days of DMARD initiation. Clinical improvement was observed in 62% of patients. RA patients treated with ICIs appears immune-related adverse events. Conventional DMARDs may contribute to manage inflammatory arthritis without significantly compromising cancer control. Further studies are needed to establish optimal treatment protocols.
Publication Details
Page(s) 1605-1613
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 5, Year: 2025

Request the full text from PASTIC

Keywords
Rheumatoid Arthritis, Immune checkpoint inhibitors, Disease-modifying antirheumatic drugs
References
Abbasi M,Mousavi MJ,Jamalzehi S MJ .2019 .Strategies toward RA therapy. J Cell Physiol, 234(7) : 10018-10031.
Alamanos Y,Drosos AA Y .2005 .Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev., 4(3) : 130-136.
Amaya-Amaya J,Botello-Corzo D,Calixto OJ D .2012 .Usefulness of patient-reported outcomes in rheumatoid arthritis. Arthritis., : 935187.
Anaya JM,Correa PA,Mantilla RD .2001 .Rheumatoid arthritis in African Colombians. , 31(3) : 191-198.
Bass AR,Abdel-Wahab N,Reid PD .2023 .Comparative safety of TNF inhibitors. , 82(7) : 920-926.
Cadena J,Vinaccia S,Pérez A,Rico MI .2003 .The impact of disease activity on quality of life in RA patients. J. Clin. Rheumatol., 9(3) : 142-150.
Coates LC,Helliwell PS .2016 .Psoriatic arthritis: Therapies and outcomes. Arthritis. Res. Ther., 18(1) : 128.
Delgado-Vega AM,Martín J,Granados J .2006 .Genetic epidemiology of RA in Latin America. , 26(4) : 562-584.
DeMaria AN .2002 .Relative risk of cardiovascular events in RA. Am. J. Cardiol., 89(1 Suppl)) : 33D-38D.
Feldmann M and Maini R N .2001 .Role of TNF in RA pathogenesis and therapy. Annu. Rev. Immunol., 19 : 163-196.
Firestein GS .2003 .Evolving concepts of RA pathogenesis. Nature, 423(6937) : 356-361.
Gregori D,Giacovelli G,Minto C .2018 .Association of treatments with pain control in osteoarthritis. J Am Med Assoc., 320(24) : 2564-2579.
Ding Karlson E W,Keenan B,B T B .2013 .Geneenvironment interactions in RA. Arthrit. Care Res., 65(8) : 1147-1156.
Lübbers J,Brink M,Van de Stadt LA,Huizinga TW .2013 .Type I IFN signature as a biomarker. , 72(5) : 776-780.
Lyseng-Williamson KA .2018 .Anakinra in Still's disease: A profile. Drugs Ther, 34(12) : 543-553.
Kolls Miossec P,JK Miossec P .2012 .Targeting IL-17 in RA. Nat. Rev. Drug Discov, 11(10) : 763-776.
Peters MJ,Symmons DP,McCarey D,Kitas GD D .2010 .EULAR recommendations for cardiovascular risk in RA. , 69(2) : 325-331.
Rindfleisch JA,Muller D JA .2005 .Diagnosis and management of RA. Am. Fam. Phys., 72(6) : 1037-1047.
Rojas-Villarraga A,Bayona J,Zuluaga N,Mejía S N .2009 .The impact of rheumatoid foot on disability. BMC Musculoskel. Dis., 10 : 67.
Rose N,Furer V,Polachek A .2024 .Immune checkpoint inhibitor-induced arthritis. Eur. J. Rheumatol., 11(1) : 27-32.
Sandoo A,Carroll D,Metsios GS,Kitas GD,Veldhuijzen van Zanten JJ .2011 .Association between endothelial function in RA. Arthritis. Res. Ther., 13(4) : R99.
Scott DL,Wolfe F,Huizinga TW .2010 .Rheumatoid arthritis. The Lancet. , 376(9746) : 1094-1108.
Smolen JS,Aletaha D,McInnes IB .2016 .RA therapies and clinical outcomes. The Lancet. , 388(10055) : 2023-2038.
Sokka T,Häkkinen A,Krishnan E,Hannonen P .2004 .Similar prediction of mortality by the health assessment questionnaire. , 63(4) : 494-497.
Van den Broek M,Dirven L,De Vries-Bouwstra J K and Allaart CF L .2012 .Radiological progression predictive of disability. , 71(9) : 1530-1533.
Van Riel PL,Fransen J .2007 .Established rheumatoid arthritis: Clinical assessments. Best Pract. Res. Clin. Rheumatol, 21(5) : 807-825.
Wolfe F .2000 .A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis, 43(12) : 2751-2761.
0

Citations

0

Downloads

81

Views